Question
How do inhaled corticosteroids benefit infants with established bronchopulmonary dysplasia (BPD)?
Answer
Inhaled corticosteroids are increasingly utilized in treating infants with established bronchopulmonary dysplasia (BPD) due to their positive impact on patient outcomes, particularly in reducing the incidence of chronic lung disease. A Cochrane Systematic Review highlights that early administration of inhaled steroids to very low birth weight infants can decrease the likelihood of death or chronic lung disease at 36 weeks postmenstrual age. However, to optimize the benefits while minimizing risks, it is essential to carefully evaluate the dosing and delivery methods. The potential neurodevelopmental risks associated with inhaled steroids necessitate a thorough risk-benefit analysis, emphasizing the need for individualized treatment plans and further research to refine their use.
This Ask the Expert is an edited excerpt from the course, Bronchopulmonary dysplasia (BPD) Historical and Scientific Update, presented by Katlyn Burr, MSM-HCA, RRT, RRT-NPS, AE-C.
Continued and its subsidiaries provide professional education authored by qualified Subject Matter Experts for continuing education purposes. These materials are intended for educational purposes and do not constitute medical advice or a substitute for individual clinical judgment. Continued is not a clinical healthcare provider; the licensed professional is solely responsible for ensuring that the application of any techniques or information presented is within their legal scope of practice and jurisdictional requirements.
